Immuron Limited
Research Immuron Limited (ANW) on Bullrun: market cap EUR 3.59M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerANW
- ExchangeF
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 3.59M
- Financial periodFY2025
- RevenueEUR 7.29M
- Revenue growth48.6%
- Net income-EUR 5.22M
- Free cash flow-EUR 6.14M
- Gross margin65.4%
Valuation Snapshot
latest market cap is EUR 3.59M.
About Immuron Limited
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection;
Frequently asked questions
What is Immuron Limited's market cap?
Immuron Limited's market capitalization is EUR 3.59M.
What does Immuron Limited do?
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products.